Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can significantly improve symptoms.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least ...

Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

We will continue to work tirelessly to improve the treatment options available ... of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription ...

Fenugreek seeds could be a gentle and effective option to help manage your eczema and improve your skin condition ...

17, 2024 – The FDA has approved a new treatment for persistent ... and older with moderate to severe atopic dermatitis, which is the most common type of eczema. Ebglyss may be used when ...